Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cv Sciences Inc (OP: CVSI )

0.0430 +0.0029 (+7.23%)
Streaming Delayed Price Updated: 3:30 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,037
Open 0.0400
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0401
Today's Range 0.0400 - 0.0497
52wk Range 0.0263 - 0.1650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CV Sciences FY22 Revenue Declines 19% To $16.2M
CV Sciences, Inc. (OTCQB: CVSI) FY 2022 revenue was $16.2 million, a 19% decrease compared to $20.0 million for 2021. Q4 2022 Financial Highlights 
Via Benzinga
CBD And Nicotine Formula To Treat Smokeless Tobacco Addiction Receives Patent From Japan, FDA Approval Next
CV Sciences, Inc. (OTCQB: CVSI) received a formal certificate of grant from the Japan Patent Office for its patent application 7216697. 
Via Benzinga

Performance

YTD
+38.71%
+38.71%
1 Month
-2.27%
-2.27%
3 Month
+38.71%
+38.71%
6 Month
+10.26%
+10.26%
1 Year
-65.87%
-65.87%

More News

Read More
Why Is CV Sciences Stock Up Today?
Via Benzinga
Biden's Pardon For Cannabis Offenders: 27 Reactions From Politicians, Industry Executives And Advocacy Orgs
Via Benzinga
The CBD Gold Rush Is Over (And That's A Great Thing For Consumers)
Via Benzinga
Marijuana As An Appetite Suppressant? It's A Possibility
Via Benzinga
CV Sciences Adds +PlusCBD Relief Softgels To Wellness Line Of CBD Products
Via Benzinga
Nutrition Giant GNC To Distribute CBD Products In 770 Stores In US
Via Benzinga
CV Sciences Q1 Revenue Down 8.33%, CEO Encouraged As PlusCBD Brand Gains Market Share
Via Benzinga
A Preview Of CV Sciences's Earnings
Via Benzinga
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
Via Benzinga
CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients
Via Benzinga
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
Via Benzinga
Trending Up: $TLLTF $VRNOF $UNRV, GOP Cannabis Bill, Cause for Hope? — Cannabis Daily November 16, 2021
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Earnings Preview For CV Sciences
Via Benzinga
Pharmaceutical & Hemp Wellness Segments Of Cannabidiol Market Could See the Fastest Growth Rates Through 2028
Via FinancialNewsMedia
EXCLUSIVE: CV Sciences Launches New Product Line Featuring Full Range Of Phytocannabinoids
Via Benzinga
Looking Into CV Sciences's Return On Capital Employed
Via Benzinga
Ryder Cup To Retirees: Many Golfers Say CBD Is A Hole In One For Their Game
Via Benzinga
Cantor Remains Neutral on Charlotte's Web, cbdMD and CV Science CBD Stocks, Sector Could Benefit From Federal Legalization
Via Benzinga
American Cannabis Operator Index Lost 0.6% This Year, Best Players In July: Columbia Care, Lowell Farms, Ayr Wellness & Ascend Wellness
Via Benzinga
Topics Cannabis
Exposures Cannabis
Slight Correction For Cannabis Stocks After A Ramping Week, Check Out The Top Movers For July 30, 2021
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Week In Cannabis: Amazon Lobbies In DC, Colombia's New Law, Big IPOs And More
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.